BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 29601329)

  • 1. HIV infection and lipids.
    Jain A; Kolvekar T; Nair DR
    Curr Opin Cardiol; 2018 Jul; 33(4):429-435. PubMed ID: 29601329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of statins in the setting of HIV infection.
    Eckard AR; McComsey GA
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):305-12. PubMed ID: 26126687
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardiovascular risk and dyslipidemia among persons living with HIV: a review.
    Maggi P; Di Biagio A; Rusconi S; Cicalini S; D'Abbraccio M; d'Ettorre G; Martinelli C; Nunnari G; Sighinolfi L; Spagnuolo V; Squillace N
    BMC Infect Dis; 2017 Aug; 17(1):551. PubMed ID: 28793863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Lipid Levels and Cardiovascular Disease in HIV-Infected Individuals: Just Give Them a Statin?
    Stein JH
    Top Antivir Med; 2016 Dec-2017 Jan; 23(5):169-73. PubMed ID: 27398770
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human Immunodeficiency Virus Infection, Antiretroviral Therapy, and Statin: a Clinical Update.
    Zanetti HR; Roever L; Gonçalves A; Resende ES
    Curr Atheroscler Rep; 2018 Feb; 20(2):9. PubMed ID: 29423787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection.
    Bowman E; Funderburg NT
    Curr HIV/AIDS Rep; 2019 Jun; 16(3):214-223. PubMed ID: 30993515
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Lipid alterations and cardiovascular risk associated with antiretroviral therapy].
    Masiá-Canuto M; Bernal-Morell E; Gutiérrez-Rodero F
    Enferm Infecc Microbiol Clin; 2006 Dec; 24(10):637-48. PubMed ID: 17194390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review.
    Lambert CT; Sandesara PB; Hirsh B; Shaw LJ; Lewis W; Quyyumi AA; Schinazi RF; Post WS; Sperling L
    HIV Med; 2016 Jun; 17(6):411-24. PubMed ID: 26611380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular implications of HIV-induced dyslipidemia.
    Giannarelli C; Klein RS; Badimon JJ
    Atherosclerosis; 2011 Dec; 219(2):384-9. PubMed ID: 21722900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating and managing cardiovascular disease risk factors in HIV-infected patients.
    Top HIV Med; 2010 Dec; 18(5):164-8. PubMed ID: 21245517
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Short communication: Lipids and cardiovascular risk after switching HIV-1 patients on nevirapine and emtricitabine/tenofovir-DF to rilpivirine/emtricitabine/tenofovir-DF.
    Rokx C; Verbon A; Rijnders BJ
    AIDS Res Hum Retroviruses; 2015 Apr; 31(4):363-7. PubMed ID: 25625211
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular disease risk factors in HIV patients--association with antiretroviral therapy. Results from the DAD study.
    Friis-Møller N; Weber R; Reiss P; Thiébaut R; Kirk O; d'Arminio Monforte A; Pradier C; Morfeldt L; Mateu S; Law M; El-Sadr W; De Wit S; Sabin CA; Phillips AN; Lundgren JD;
    AIDS; 2003 May; 17(8):1179-93. PubMed ID: 12819520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of four international cardiovascular disease prediction models and the prevalence of eligibility for lipid lowering therapy in HIV infected patients on antiretroviral therapy.
    Begovac J; Dragović G; Višković K; Kušić J; Perović Mihanović M; Lukas D; Jevtović Đ
    Croat Med J; 2015 Feb; 56(1):14-23. PubMed ID: 25727038
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.
    Troll JG
    Curr Atheroscler Rep; 2011 Feb; 13(1):51-6. PubMed ID: 21181310
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV infection and cardiovascular disease.
    Hemkens LG; Bucher HC
    Eur Heart J; 2014 Jun; 35(21):1373-81. PubMed ID: 24408888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triad of the Ischemic Cardiovascular Disease in People Living with HIV? Association Between Risk Factors, HIV Infection, and Use of Antiretroviral Therapy.
    Zanetti HR; Mendes EL; Palandri Chagas AC; Gomes Douglas MO; Paranhos Lopes LT; Roever L; Gonçalves A; Santos Resende E
    Curr Atheroscler Rep; 2018 May; 20(6):30. PubMed ID: 29777448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid metabolism in treated HIV Infection.
    Dubé MP; Cadden JJ
    Best Pract Res Clin Endocrinol Metab; 2011 Jun; 25(3):429-42. PubMed ID: 21663837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiovascular complications and atherosclerotic manifestations in the HIV-infected population: type, incidence and associated risk factors.
    Boccara F
    AIDS; 2008 Sep; 22 Suppl 3():S19-26. PubMed ID: 18845918
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dyslipidaemia and cardiovascular risk in HIV infection.
    Kulasekaram R; Peters BS; Wierzbicki AS
    Curr Med Res Opin; 2005 Nov; 21(11):1717-25. PubMed ID: 16307691
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.